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Abstract 
Histidine-rich glycoprotein (HRG) is synthe-
sized by liver and is present at relatively high
concentration in the plasma of vertebrates. We
have previously described the association of a
HRG-like molecule to purified rabbit skeletal
muscle AMP deaminase (AMPD). We also pro-
vided the first evidence for the presence of a
HRG-like  protein  in  human  skeletal  muscle
where a positive correlation between HRG con-
tent and total determined AMPD activity has
been shown. In the present paper we investi-
gate the origin of skeletal muscle HRG. The
screening of a human skeletal muscle cDNA
expression library using an anti-HRG antibody
failed to reveal any positive clone. The RT-PCR
analysis, performed on human skeletal muscle
RNA  as  well  as  on  RNA  from  the  rhab-
domyosarcoma (RD) cell line, failed to show
any mRNA specific for the plasma HRG or for
the putative muscle variant. When the RD cells
were  incubated  with  human  plasma  HRG,  a
time-dependent  increase  of  the  HRG
immunoreactivity  was  detected  both  at  the
plasma  membrane  level  and  intracellularly.
The internalisation of HRG was inhibited by
the addition of heparin. The above data strong-
ly suggest that skeletal muscle cells do not syn-
thesize the muscle variant of HRG but instead
can actively internalise it from plasma.
Introduction 
The  histidine-rich-glycoprotein  (HRG),  a
member of the cystatin superfamily, is a single
chain  glycoprotein  of  approximately  75  kDa
that is present at a relatively high concentra-
tion in the plasma of vertebrates (100-200 ʼg/mL 
in humans).1 HRG is a multidomain polypep-
tide consisting of two cystatin-like regions at
the  N-terminus,  a  central  histidine-proline-
rich region and a C-terminal domain. HRG can
bind to a variety of ligands such as fibrinogen,
plasminogen,  heparin,  heparan  sulphate,
tropo  myosin  and  divalent  transition  metal
cations.  Its  multidomain  structure  suggests
that the molecule may act as an adaptor pro-
tein that can bring together different ligands
under  specific  conditions.  The  physiological
role of HRG is still to be established, although
it has been implicated in a number of cellular
processes including blood coagulation and fib-
rinolysis,  angiogenesis,  immune  complex
clearance,  cell  adhesion  and  cell  migration.2
HRG is synthesized in parenchymal liver cells,3
although some studies have suggested that it
may also be produced by immune cells such as
monocytes  and  macrophages4 and  by
megakaryocytes.5 The  tissue  distribution  of
mouse HRG mRNA, investigated by Northern
blot analysis performed on total RNA from liver,
spleen, thymus, heart, lung, kidney, brain and
testis, demonstrated that HRG mRNA is pro-
duced  only  in  the  liver.6 The  same  authors
reported  that  the  RT-PCR  analysis  failed  to
detect any HRG mRNA in immune tissues, sug-
gesting that the HRG found in immune cells
must be acquired from plasma. This hypothe-
sis is supported by a study of Olsen et al. that
demonstrated  the  binding  of  HRG  to  T-cell
lines and its active internalisation.7
We have previously described the associa-
tion of a HRG-like molecule to purified rabbit
skeletal muscle AMP deaminase (AMPD).8 In
comparison  with  mature  plasma  HRG,  the
AMPD-associated variant probably contains a
unique  N-terminal  extension.8 These  results
suggest that a possible mechanism for the pro-
duction of this novel HRG isoform is the alter-
native splicing of the HRG primary transcript,
forming an mRNA encoding a variant with a
unique  N-terminus  spliced  onto  the  mature
HRG polypeptide. 
We have also provided the first evidence for
the  presence  of  this  HRG-like  protein  in
human  skeletal  muscle9 demonstrating  the
selective binding of an anti-HRG antibody to
type IIB fibers and suggesting a preferential
association of muscle HRG to the AMPD iso-
form M that is predominant in fast-twitch gly-
colitic fibers. Moreover, in a recent immuno-
histochemical analysis, performed on human
skeletal muscle biopsies of patients affected by
AMPD  deficiency,  we  have  shown  a  positive
correlation between the HRG muscle content
and the total determined AMPD activity.10 We
previously suggested a new model for skeletal
muscle AMPD, a 1:1 molecular adduct in which
two  AMPD  catalytic  subunits  assemble  with
two HRG subunits.11 However, the present data
do  not  establish  whether  HRG  permanently
contributes to the structure of the enzyme or
whether  it  simply  binds  the  enzyme.
Altogether, these observations prompted us to
investigate the origin of skeletal muscle HRG
in order to clarify whether this HRG variant is
synthesized by the muscle cells or is acquired
from plasma.
Materials and Methods
Reagents
Analytical grade reagents were used in all
experiments.  Phosphocellulose  resin  (P-11)
was  supplied  by  Whatman  International
(Maidstone, UK). Cell culture reagents were
purchased  from  Biowittaker  Cambrex
(Walkersville, MD, USA).
Tissue samples and rhabdomyosar-
coma cell line
Two  human  biopsy  specimens,  one  from
liver and the other from quadriceps femoris,
were obtained from patients who underwent
surgery for diagnostic purposes, following pro-
cedures  approved  by  the  University  Hospital
Ethics Committee, Pisa, Italy. Both tissue sam-
ples showed no histological or histochemical
abnormalities on examinations.
The human embryonic rhabdomyosarcoma
(RD) cell line was provided by the Lombardia
and  Emilia  Experimental  Zooprophylactic
Institute  (Brescia,  Italy).  The  RD  cells  were
cultured at 37°C in the presence of 5% CO2 in
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the growth medium suggested by the provider
and consisting of Minimum Essential Medium
supplemented  with  10%  fetal  bovine  serum
(FBS),  non-essential  amino  acids,  vitamins
(B1, B2, B3, B6, folic acid, I-inositol, D-calcium
pantothenate, choline chloride) and penicillin-
streptomycin.
Purification of histidine-rich-glyco-
protein
Human plasma HRG was purified according
to the method of Rylatt et al.12 Briefly, a phos-
phocellulose  column  was  first  precycled
according to the manufacturer’s instructions
and equilibrated with a loading buffer contain-
ing 0.5 M NaCl, 1 mM EDTA, 1 mM dithiothre-
itol (DTT) and 10 mM sodium phosphate (pH
6.8). Human plasma from a healthy donor was
collected by centrifugation at 1000 x g for 20
min, and NaCl and EDTA were added to give a
final concentration of 0.5 M and 1 mM, respec-
tively.  The  plasma  was  passed  through  the
equilibrated  column;  the  resin  was  first
washed with loading buffer containing 0.8 M
NaCl and bound HRG was then eluted using
loading buffer containing 2 M NaCl. The purity
of HRG preparations (>95%) was evaluated by
a 10% SDS-PAGE and Western blot analysis.
The  concentration  of  HRG  was  determined
using the Bio-Rad protein assay kit (Bio-Rad,
Hercules, CA, USA) with BSA as standard.
Screening of a cDNA expression
library
A human skeletal muscle cDNA expression
library prepared in the Lambda ZAP II vector
(Stratagene, La Jolla, CA, USA) was screened
for cDNAs coding for the HRG protein accord-
ing to Sambrook et al.13 Briefly, approximately
2ﾥ106 plaques were screened by employing the
rabbit anti-HRG antibody that we have previ-
ously  described  (1:10000)9 and  a  peroxidase
labelled goat anti-rabbit IgG (1:5000) (Sigma,
St.  Louis,  MO,  USA)  as  secondary  antibody.
The  nitrocellulose  membranes  were  then
developed with the Immun-Star HRP chemilu-
minescent kit (Bio-Rad).
Primer design
The sequences of the oligonucleotides used
for the RT-PCR analysis are reported in Table 1.
The  paired  primers  HRG-1/HRG-2  and  HRG-
3/HRG-4 were used to amplify the full length
and the 974-1377 region of the HRG mRNA,
corresponding to PCR products of 1691 bp and
404  bp,  respectively.  The  HRG-5  degenerate
primer was designed to amplify, together with
the HRG-2 primer, a 268 bp fragment corre-
sponding to the mRNA region coding for the
sequence recognized by the rabbit anti-HRG
antibody that was used in this study. 
RT-PCR analysis
Total  RNA  from  human  skeletal  muscle,
human liver and RD cell line was extracted by
using  the  TRIzol  reagent  (Invitrogen,
Carlsbad, CA, USA). One ʼg of each sample
was then submitted to Dnase I (Sigma) treat-
ment according to the manufacturer’s instruc-
tions, to remove contaminating genomic DNA.
Reverse transcription was then performed at
42°C for 1 h as follows: 1 ʼg of each sample
was mixed with a solution containing 4 mM
MgCl2, 50 mM KCl, 50 mM Tris/HCl (pH 8.3), 1
mM  each  dNTP,  0.2  ʼg  Random  Hexamer
(Fermentas,  York,  UK),  20  U  Ribonuclease
inhibitor  (Fermentas),  200  U  RevertAid  M-
MuLV reverse transcriptase (Fermentas) in a
final volume of 20 ʼL. 
The PCR reaction (25 ʼL final volume) was
carried out using 5 ʼL of each cDNA sample in
a solution containing 1.5 mM MgCl2, 50 mM
KCl, 20 mM Tris/HCl (pH 8.3), 0.2 mM of each
dNTP,  0.2  ʼM  of  each  primer  and  1  U  of
Platinum Taq DNA Polymerase (Invitrogen).
The  amplification  program  to  obtain  the
HRG full length cDNA was set to denature at
94°C  for  30  s,  anneal  at  52°C  for  30  s  and
extend  at  72°C  for  2  min  (for  35  cycles),
whereas that to amplify the 974-1377 and 1540-
1807 regions of HRG cDNA as well as the ʲ-
actin cDNA fragment was set at 94°C for 30 s,
at 52°C for 30 s and at 72°C for 30 s (for 40
cycles). The PCR products were separated on a
2% agarose gel and stained with ethidium bro-
mide. The absence of contaminants was rou-
tinely checked by running control samples that
contained no RNA, no reverse transcriptase or
only the PCR reaction buffer. The quality of all
RNA samples was tested by a 2% denaturing
agarose gel and by RT-PCR analysis for human
ʲ-actin that gave the expected PCR product of
295 bp in all samples.
SDS-PAGE and Western blot analysis
Electrophoresis in the presence of SDS was
carried  out  in  a  10%  polyacrylamide  gel  as
described by Laemmli.15 The RD cells extract
used for SDS -PAGE was obtained as follows;
10ﾥ106 RD cells were lysed using 50 ʼL of a
lysis  buffer  containing  10  mM  Tris/HCl  (pH
7.6), 150 mM NaCl, 1 mM EDTA, 1% Triton X-
100,  plus  a  cocktail  of  protease  inhibitors
(Sigma):  12  ʼM  leupeptin,  100  ʼM  phenyl-
methylsulfonylfluoride,  10  ʼM  pepstatin  A.
Centrifugation (10 min at 12,000 x g at 4°C)
allowed  recovery  of  the  cytosoluble  protein
fraction (cytosol).
Precision  Plus  Protein  molecular  weight
standards (Bio-Rad) were used to calibrate the
gel. After the SDS-PAGE, samples were electro-
transferred to a nitrocellulose membrane. The
blot was blocked using 5% non-fat milk in tris-
buffered saline (TBS) for 1 h at room temper-
ature  and  then  treated  with  the  previously
described  rabbit  anti-HRG  antibody9 diluted
1:5000 (v/v) in 5% non-fat milk in TBS (1 h at
room temperature). After washing with 0.5%
Tween-20 in TBS, the blot was incubated with
a goat anti-rabbit IgG peroxidase labelled poly-
clonal antibody (Sigma) diluted 1:10000 (v/v)
in 5% non-fat milk in TBS (1 h at room temper-
ature) and then extensively washed with 0.5%
Tween-20  in  TBS  and  developed  using  the
Immun-Star HRP chemiluminescent kit (Bio-
Rad). Controls included the omission of pri-
mary  antibody  and  substitution  of  immune
serum by pre-immune or non-immune rabbit
serum.
Treatment of rhabdomyosarcoma
cells with human plasma histidine-
rich-glycoprotein
Five ﾥ104 RD cells/well were plated in 8-well
chamber-slides  (Nalge  Nunc  International,
Naperville, IL, USA) and incubated in complete
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Table 1. Sequences of the oligonucleotides used for the RT-PCR analysis and primer location.
Oligonucleotides Nucleotide Polarity Sequences References
positions
HRG-1 117-135 + 5’-TAACAAAATGAAGGCACTC-3’ Koide et al.3
HRG-2 1784-1807 - 5’-AGTATGAAAGTAGGTTGAAAAGAA-3’ Koide et al.3
HRG-3 974-994 + 5’-GATCATCATCATCCCCACAAG-3’ Koide et al.3
HRG-4 1358-1377 - 5’-GGGTCACAAGGTCCATAGTC-3’ Koide et al.3
HRG-5 1540-1556 + 5’-CCTGARGCCAAYTTYCC-3’ Koide et al.3
ACTIN-1 549-573 + 5’-TCACCCACACTGTGCCCATCTACGA-3’ Ponte et al.14
ACTIN-2 819-843 - 5’-CAGCGGAACCGGTCATTGCCAATGG-3’ Ponte et al.14[European Journal of Histochemistry 2011; 55:e6] [page 35]
growth medium (300 ʼL/well) at 37°C with 5%
CO2. After 24 h, the medium was replaced with
serum-free medium (200 ʼL/well) to remove
potentially  cell-bound  or  cell-internalised
bovine HRG derived from FBS contained in the
complete culture medium. After further 30 h
incubation, human plasma HRG (200 or 400
ʼg/mL) was added to the wells filled with a
new  serum-free  medium  containing  20  ʼM
zinc and the cells were kept at 37°C for further
15 min, 30 min or 4 h. The cells were then
washed twice with PBS, fixed in PBS contain-
ing 3.6% paraformaldehyde (20 min at room
temperature) and submitted to immunocyto-
chemistry for HRG. Control incubations were
performed  without  the  addition  of  HRG.
Internalisation experiments were also carried
out in the absence of zinc and also by incubat-
ing for 30 min the RD cells with 200 ʼg/mL
HRG  and  200  ʼg/mL  heparin  from  porcine
intestinal mucosa. All experiments were per-
formed in duplicate and repeated four times.
The  cells  used  for  the  assays  were  in  their
exponential growth phase and showed a viabil-
ity exceeding 95% even after the 30 h incuba-
tion with serum free medium, as determined
by the Trypan blue exclusion test.
Immunocytochemistry for histi-
dine-rich-glycoprotein
Pre-fixed cells were first washed with dis-
tilled water and then with PBS to remove free
paraformaldehyde.  Permeabilized  cells  were
prepared by incubation with 0.2% Triton X-100
in  PBS  (10  min  at  room  temperature)
(Sigma). Permeabilized and unpermeabilized
cells were then treated with a 0.06% H2O2 /PBS
solution to quench the endogenous peroxidase
activity  and  subsequently  incubated  at  37°C
with  5%  swine  serum  (Dako,  Glostrup,
Denmark) to block non-specific reactivity. The
samples were then incubated overnight at 4°C
with the previously described9 rabbit anti-HRG
polyclonal  antibody  (1:4000  in  5%  BSA/0.2%
gelatin-PBS). The detection protocol was car-
ried out using biotinylated link antibodies and
a streptavidin-peroxidase complex (LSAB kit,
Dako). Among each step, slides were rinsed in
Triton  (0.01%)  and  washed  with  PBS.  The
reaction was developed by incubating for 5 min
the samples in a substrate-chromogen solution
(3,3’-diaminobenzidine, Sigma), in the dark.
After  haematoxylin  counterstaining,  samples
were  dehydrated  and  mounted  using  DPX
mountant  (Fluka,  Buchs,  Switzerland).
Negative controls were obtained omitting the
primary  antibody  and  incubating  the  speci-
mens with 5% BSA/0.2% gelatin-PBS or with
pre-immune rabbit serum (1:4000 in 5% BSA
/0.2% gelatin-PBS). All steps were performed at
room temperature unless otherwise specified.
The  number  of  immunoreactive  cells  was
calculated by two independent observers out of
a total of 500 randomly selected cells per sam-
ple. Statistical analysis of the differences in the
positive  cells  number  between  samples  was
performed by the parametric Student t-test.
Results
Studies to verify the expression 
of histidine-rich-glycoprotein
mRNA in skeletal muscle
With the purpose to isolate the full length
cDNA sequence of the putative muscle specific
form of HRG, a human skeletal muscle cDNA
expression library was screened with a rabbit
antibody, specific for the C-terminal region of
human plasma HRG, that has been shown to
bind to type IIB fibers in human skeletal mus-
cle.9,10 However,  no  positive  clone  could  be
identified following this procedure.
A  human  quadriceps  femoris  biopsy  was
processed  for  Western  Blot  analysis  and
immunohistochemistry  using  an  anti-HRG
antibody as previously described.10 A positive
reaction was observed by both techniques con-
firming, in this specimen, a clear prevalence of
HRG in the type IIB fibers (results not shown).
Total RNA was then extracted from the biopsy,
reverse transcribed and submitted to PCR. The
sequences of the oligonucleotides used for the
RT-PCR analysis are reported in Table 1. The
primers HRG-1 and HRG-2 were designed to
amplify the HRG full length cDNA and HRG-3
together with HRG-4 to amplify a portion of the
exon 7 encoding a histidine-rich region of the
protein.  In  addition,  primer  HRG-2  together
with the degenerate primer HRG-5 were used
to amplify the cDNA sequence encoding the C-
terminal region of plasma HRG that, according
to our immunological analysis, is conserved in
the muscle-specific form of HRG.9,10 No PCR
product was obtained from muscle RNA under
any of the above described conditions. When
the above described RT-PCR analysis was per-
formed on total RNA extracted from the human
embryonal  rhabdomyosarcoma  RD  cell  line,
the results were completely negative. In con-
trast, when human liver mRNA was used as
positive  control,  three  PCR  products  were
obtained, corresponding to the HRG full length
cDNA (1691 bp), to the 974-1377 cDNA region
(404  bp)  and  to  the  sequence  encoding  the
HRG C-terminal region (268 bp) (Figure 1).
Internalisation of histidine-rich-
glycoprotein by rhabdomyosarco-
ma cells
The  use  of  a  rabbit  anti-HRG  antibody
allowed  us  to  demonstrate  the  presence  in
skeletal  muscle  of  an  immunoreactivity  that
gave rise to two bands with apparent molecular
weight values of 95 and 70 kDa,10 correspon-
ding to those determined for the HRG compo-
nent of skeletal muscle AMPD before and after
deglycosylation.16 By Western blot analysis of
the RD cells, carried out as described under
Materials and Methods using the same anti-
body, no immunoreactive band could be detect-
ed (results not shown). In order to investigate
whether HRG could be internalised by muscle
cells,  experiments  were  conducted  in  which
the RD cells were incubated at 37°C with plas-
ma  HRG  in  the  growth  medium  described
under Materials and Methods with the addition
of 20 ʼM ZnCl2, this concentration of zinc was
used as it is the physiological blood concentra-
tion of zinc and has been shown to be the opti-
mal one for HRG binding to most cell lines.17
Immunocytochemistry for HRG, performed at
various times of incubation, was carried out on
permeabilised or unpermeabilised cells to ver-
ify  whether  HRG  was  really  internalised  or
simply passively absorbed on to the cell surface
(Figure 2).
Whilst there was no apparent staining in the
control  RD  cells  incubated  for  4h  in  the
absence of plasma HRG (Figure 2d), the pres-
ence  of  the  protein  in  the  growth  medium
caused its internalisation by the RD cells as
evidenced  by  the  time  course  of  the
immunoreaction performed on permeabilised
cells.  In  particular,  after  15  min  incubation
with  200  ʼg/mL  HRG,  only  a  few  RD  cells
exhibited  an  immunoreactivity  that  was
localised on the external side of the plasma
membrane (Figure 2a). When the incubation
was prolonged to 30 min, an increase of the
number  of  the  reactive  cells  was  observed
(7.6±1.3%).  The  immunoreactivity  was  still
generally localised on the plasma membrane,
although in a small number of cells immunore-
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Figure 1. RT-PCR analysis. The indicated
sizes of the amplified products correspond
to the full length and to the 974-1377 and
1540-1807 regions of HRG cDNA. A con-
trol  PCR  for  ʲ-actin  is  also  shown.  L,
human liver (control); SM, human skeletal
muscle; RD, RD cell line.[page 36] [European Journal of Histochemistry 2011; 55:e6]
activity could clearly be detected intracellularly
(Figure 2b). When the incubation was carried
out for 4 h, the percentage of the positive RD
cells  increased  significantly  (16.6±3.9%;
P=0.005). The intensity of the immunostain-
ing was similar to that of 30 min samples, but
appeared to be mainly localised at the cyto-
plasm level, although it could not be related to
any distinct subcellular region or compartment
(Figure 2c). 
When the incubation of RD cells was carried
out  using  a  higher  HRG  concentration  (400
ʼg/mL),  the  RD  cells  exhibited  a  stronger
intensity  of  immunostaining  but  the  time-
dependent internalisation of HRG as well as
the proportion of HRG positive cells and the
pattern  of  protein  distribution  resulted
unchanged compared to that observed in the
experiment carried out using 200 ʼg/mL HRG
(Figures 2e and 2f). No positive staining could
be detected when the RD cells were incubated
for 4 h in the presence of 200 ʼg/mL or 400
ʼg/mL HRG without the addition of zinc (data
not shown). When the immunocytochemistry
was carried out on unpermeabilised RD cells
incubated up to 4 h with HRG, the immunos-
taining was localised on the plasma membrane
(insert  of  Figure  2c),  without  any  apparent
change  of  the  localisation  observed  after  15
min incubation (insert of Figure 2a).
Altogether, the results obtained with perme-
abilised  and  unpermeabilised  cells  give  evi-
dence that HRG is internalised by the RD cells. 
Effect of heparin on histidine-
rich-glycoprotein internalisation by
rhabdomyosarcoma cells
HRG has been reported to interact with the
sulphated  glycosaminoglycan  (GAG)  heparin
with a 1:1 stoichiometry, to form a high affini-
ty complex with a Kd of 7 nmol/L.18 Moreover,
heparan  sulphate  proteoglycans  are  ubiqui-
tously  expressed  on  animal  cell  surfaces19
including muscle cells during myogenic differ-
entiation.20 These  observations  suggest  that
the  above  described  HRG  uptake  by  the  RD
cells could occur through the binding of the
protein to heparan sulphate GAGs localised on
the cell surface. In order to examine this pos-
sibility, we studied the effect of the addition of
heparin, at 6 fold higher ratio to HRG, to the
incubation mixture used for the internalisa-
tion experiments. 
After  30  min  incubation  with  200  ʼg/mL
HRG in the presence of 200 ʼg/mL heparin, the
percentage  of  immunostained  RD  cells
(4.2±0.5%)  was  significantly  reduced
(P=0.004) in comparison with that determined
in  the  control  samples  incubated  in  the
absence of heparin (Figure 3), clearly indicat-
ing  an  inhibitory  effect  of  heparin  on  the
uptake of HRG by the RD cells.
Discussion 
The  characterization  of  HRG  as  a  plasma
protein  is  well  established.21 We  previously
reported the existence of a HRG-like molecule
associated with skeletal muscle AMPD.8,9,16 In
the present paper we have investigated the ori-
gin of skeletal muscle HRG in order to clarify
whether this HRG variant is synthesized by the
muscle cells or is acquired from plasma.
The  observations  reported  in  the  present
work  indicate  that  skeletal  muscle  does  not
express  plasma  HRG  mRNA,  extending  the
negative  results  previously  reported  for  this
protein in several other tissues6 and thereby
confirming  that  plasma  HRG  is  synthesized
only  by  parenchimal  liver  cells.3 No  product
was obtained when the RT-PCR analysis was
performed  on  human  skeletal  muscle  using
primers specific to either the full length or an
exon 7 region of plasma HRG mRNA. 
The above observations do not exclude the
possibility that a tissue specific form of HRG
mRNA could be expressed by muscle, as our
previous studies have shown that the HRG-like
molecule isolated from purified rabbit skeletal
muscle AMPD is an isoform of the plasma pro-
tein.8 This hypothesis can be rejected, howev-
er,  since  our  investigation  showed  the  total
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Figure 2. Internalisation of plasma HRG by RD cells. RD cells were incubated in a medium con-
taining human plasma HRG, fixed in 3.6% paraformaldehyde and submitted to immunocyto-
chemistry performed on permeabilised or unpermeabilised cells, as described under Materials
and  Methods.  The  pictures  show  permeabilized  RD  cells  incubated  in  the  presence  of 
200 µg/mL HRG for 15 min (a), 30 min (b) and 4 h (c), or in the presence of 400 µg/mL HRG
for 30 min (e) and 4 h (f). The inserts of panels (a) and (c) show the immunoreactivity of unper-
meabilized RD cells incubated in the presence of 200 µg/mL HRG for 15 min and 4 h, respec-
tively. (d) permeabilized RD cells incubated for 4 h in the absence of HRG. Scale bars: 25 µm.
Figure 3. Effect of heparin on the internal-
isation  of  HRG  by  RD  cells.  Cells  were
incubated with 200 µg/mL plasma HRG,
in the absence (n) or in the presence (£) of
heparin (200 µg/mL), as described under
Materials  and  Methods.  The  histograms
represent  the  average  number  of
immunoreactive cells, calculated from the
observation of 500 randomly selected cells
from each sample. Error bars represents the
standard error. Differences were considered
significant at P<0.01. *P=0.004.[European Journal of Histochemistry 2011; 55:e6] [page 37]
absence of any muscle specific HRG mRNA. A
human  skeletal  muscle  cDNA  expression
library was screened with an anti-HRG anti-
body  specific  for  the  C-terminal  region  of
human plasma HRG, that has been shown to
bind to type IIB fibers in human skeletal mus-
cle,9,10 but no positive clone could be identified.
In addition, the RT-PCR analysis performed on
total RNA extracted from human skeletal mus-
cle  with  a  degenerate  primer,  designed  to
amplify the mRNA region encoding for the C-
terminal sequence of HRG recognized by the
anti-HRG antibody, failed to detect any product.
All the above negative results clearly indicate
that the HRG-like molecule associated to skele-
tal muscle AMPD is not synthesized by human
skeletal muscle fibers.
The present paper reports a further investi-
gation that demonstrates that plasma HRG can
be internalised by skeletal muscle fibers. The
incubation of human RD cells in a medium con-
taining human plasma HRG resulted in a pro-
gressive time-dependent uptake of the protein
as  detected  by  immunocytochemistry,  estab-
lishing that muscle cells can internalise HRG. 
Previous  studies  have  shown  that  plasma
HRG binds to many cell types, the localisation of
the protein to the cell surface being generally
mediated  by  heparan  sulphate,17,22 although
other cell surface receptors have been described
including  tropomyosin,23 FcR,24 and  ATP  syn-
thase.25 In contrast, the only study reporting the
internalisation of HRG is that by Olsen et al.7
showing that HRG can be actively internalised
by the human T-cell line MT4 via the interaction
of the protein to cell surface GAGs. 
It should be noted that only a limited num-
ber of RD cells were able to bind and inter-
nalise  HRG.  After  4  h  incubation  with 
200 ʼg/mL HRG, the percentage of immunore-
active RD cells was 16.6%. When the uptake
experiments were carried out using a higher
HRG  concentration  (400  ʼg/mL),  a  stronger
immunoreactivity  could  be  detected  but  the
proportion  of  positive  cells  remained
unchanged; this observation is totally consis-
tent with that reported for MT4 cells (15-20 %)
after a similar treatment.7 We also observed an
inhibitory effect of heparin on the uptake of
HRG,  strongly  suggesting  that  the  protein
binds to RD cells via GAGs. However, an excess
of heparin caused only a 50% reduction of the
HRG binding to RD cells, whereas a percentage
of inhibition higher than 90% was previously
reported for the HRG binding to the T-cells.7
Although our data can not exclude a heparan
sulphate-independent binding of HRG to RD
cells, the limited inhibitory effect of heparin
on the HRG binding could be explained by the
different cell type used in our study. RD cells
are  poorly  differentiated  since  they  are  an
embryonic rhabdomyosarcoma cell line; it is
therefore possible that more highly differenti-
ated cells might demonstrate a more efficient
uptake of the protein. Crucial events in myoge-
nesis rely on the highly regulated spatiotempo-
ral  distribution  of  cell  surface  heparan  sul-
phate proteoglycans to which growth factors
are associated; in addition, the composition of
GAG species is modified during myogenic dif-
ferentiation,  in  particular  heparan  sulphate
levels that are increased during this process.20
Moreover, heparan sulphate species from dif-
ferent  tissue  sources  differ  in  charge  and
domain  organisation.26-28 Further  studies  are
in progress to evaluate the role of myogenic
differentiation on the capability of HRG inter-
nalisation.
HRG is known to bind a variety of ligands,
including heme and divalent cations.29 It has
been established that HRG from rabbit serum
binds  Hg2+,  Cu2+,  Zn2+,  Ni2+,  Cd2+,  Co2+ in
descending order of binding affinity and with
an apparent stoichiometry of 10 (Cu2+, Co2+,
Ni2+ and Hg2+) to 20 (Zn2+ and Cd2+) metal ions
bound per HRG molecule.30,31 Altogether, these
results  may  be  interpreted  as  an  indication
that  most  of  such  a  large  number  of  metal
binding sites are non-specific and most of the
zinc is simply adventitiously bound. More pos-
itive conclusions can be reached by taking in
consideration the available data on the charac-
terization of the zinc binding site of HRG. The
interaction between plasma HRG and Zn2+ is
abolished when histidine residues are chemi-
cally removed from HRG, supporting the model
that histidine residues are essential for Zn2+
binding.30 We previously reported that the HRG
molecule  associated  with  skeletal  muscle
AMPD  can  be  isolated  from  the  enzyme  by
zinc-affinity  chromatography.16 In  a  recent
study, we have characterized the zinc-binding
site of the isolated HRG. X-ray absorption spec-
troscopy analysis of a 2:1 zinc-HRG complex
has shown that zinc is bound to the protein in
a  dinuclear  cluster  where  each  Zn2+ ion  is
coordinated to histidine ligands and the sulfur
donated  by  a  cysteine.  On  the  basis  of  this
work, we suggested that Cys-294 that seems to
belong to a loop connecting a Pro-rich region
to a His-rich region is the most probable candi-
date for zinc ligation.11
The vast majority of Zn2+ in the blood (~20
ʼM) is bound to human serum albumin since
the  serum  concentration  of  this  protein  is
higher  than  that  of  HRG  (~250  ʼM  vs.  2.5
ʼM).31Therefore, it can be concluded that HRG
has no role in the chelation of Zn2+ and other
metals to protect blood and endothelial cells
from the otherwise toxic concentrations pres-
ent  in  the  circulation.  On  the  contrary,  the
exceptionally  high  level  of  zinc  in  skeletal
muscle (1 mM) coupled to the very low cyto-
plasmic free zinc concentration (about 0.1 nM)
suggests that HRG could exert a central role for
the physiological functions of Zn2+ inside mus-
cle cells, making intracellular free zinc avail-
able for specific metalloproteins. The binding
of  Zn2+ by  the  isolated  HRG  component  of
skeletal  muscle  AMPD  as  well  as  by  plasma
HRG exhibits a positive cooperativity so that
the  apparent  KdHRG (1-4  ʼM)  may  understi-
mate  its  true  affinity.11,31 Interestingly,  the
characterization of skeletal muscle AMPD as a
zinc  metalloenzyme  was  previously  report-
ed32,33 and the evidence of a dinuclear zinc site
in the catalytic subunit of the rabbit enzyme
has recently been provided.34
The complete separation of the HRG mole-
cule  associated  with  rabbit  skeletal  muscle
AMPD induced a marked reduction in the solu-
bility of the enzyme, strongly suggesting a role
of HRG in increasing the stability of the molec-
ular structure of the enzyme. Moreover, AMPD
fractions  with  a  different  stoichiometry  of
association  between  HRG  and  the  catalytic
subunit  showed  different  kinetic  behaviour
indicating that the HRG component is also crit-
ical for a stable AMPD activity.16On the basis of
these results, we concluded that the HRG com-
ponent  of  AMPD  behaves  as  a  zinc  metal-
lochaperone.11,34 In  this  view,  HRG  may
enhance  the  stability  of  AMP  deaminase  in
vivothrough insertion of zinc or by modulating
the availability of intracellular zinc. The evi-
dence given by the present paper, that plasma
HRG can be internalised by muscle cells in the
presence of 20 ʼM zinc but not in its absence,
strengthens  the  hypothesis  that  HRG  could
play a role as metallochaperone for the traffick-
ing of Zn2+ ions from plasma to muscle cells.
We have also previously suggested that the
reported  rapid  disappearance  of  AMPD  from
the circulation due to the binding and internal-
ization of the enzyme by the hepatocytes,35 is
promoted by the interaction of the HRG compo-
nent of AMPD with cell surface heparan sul-
phate.8 On the basis of the observations of the
present paper, such a phenomenon can rea-
sonably be extended to the partitioning of the
enzyme between plasma and skeletal muscle
cells.  In  comparison  with  plasma  HRG,  the
muscle variant has been reported to contain a
unique  N-terminal  extension  that  has  been
ascribed to a possible alternative splicing of
the HRG primary transcript.8
The available data are not sufficient to hypoth-
esize any role played by the N-terminal extension
neither for the reported predominance of muscle
HRG in type IIB fibers9nor for the docking of this
protein with skeletal muscle fibers. To address
these issues, is our intention to extend the inter-
nalisation experiments to the use of the HRG
variant isolated from skeletal muscle. 
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